CONCLUSION: MINIMIZING THE PAIN OF TRANSFORMATION
The connected health market is heating up, with competitors, startups, and deep-pocketed big tech all regularly launching new digital medical products. Taking too long to get to market means missed opportunities. But substandard products could spell the end of a business line. Putting the right fundamentals in place accelerates time to market, while reducing risk at every step.Many in the medical industry already have programs designed to address these concerns. But many still struggle with the complexity, the breadth of change that comes with a connected ecosystem, and the addition of the whole new area of regulated medical device software to their business.
Recognizing this, Capgemini has developed a suite of offerings, called Intelligent Medical Products and Systems (IMPS), which can support the whole software development lifecycle. Our recent approval to act as a legal manufacturer means that we can take on the entire SaMD development program, from end to end. This combines our development capacity, software architecture capabilities, world-class human-factor design studios, and test automation strategy and tactics – all supported by a harmonized global approach to risk and quality management. All this gives us the confidence to take on the risk of taking products all the way to regulated markets on behalf of our clients.
Learn more about our Intelligent Medical Product & Systems Offer and Legal Manufacturer Services. To discuss the issues raised in this document or find out more about how Capgemini can help, please contact our experts:
Andrew KoubatisIntelligent Medical Products and Systems Lead, Capgemini Engineering
Mark HerseySoftware Solution Director for Life Sciences, Capgemini Engineering
